Advances in positron emission tomographic imaging of lung cancer.
Advances in positron emission tomographic imaging of lung cancer.
复制标题
DOI：
10.1513/pats.200507-075ds
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Dehdashti, Farrokh
中科院分区：
文献类型：
--
作者：
Chen, Delphine L;Dehdashti, Farrokh
正电子发射断层扫描（PET）与[18F]氟脱氧葡萄糖（FDG）已被确立为治疗非小细胞肺癌患者的有用工具，并有望在其他癌症的临床治疗中发挥同样的价值。FDG PET成像可以评估肿瘤体内糖代谢；然而，许多其他PET示踪剂正被用于肿瘤学研究，以评估与细胞恶性转化相关的其他细胞过程的变化。[11C]-标记蛋氨酸和胆碱被用来评估细胞膜合成的变化；然而，小型研究并未显示这些示踪剂的附加信息在临床上有用。DNA合成可以通过测量胸腺嘧啶类似物3'-脱氧-3'-[18F]氟胸腺嘧啶的摄取来评估，这可能更具体地用于评估恶性肿瘤，而不会出现炎性病变假阳性结果的问题，如FDG。用铜标记的二乙酰-双（N(4)-甲基硫代氨基脲）或[18F]氟咪唑进行肿瘤缺氧成像可能提供一种更好的方法来预测哪些肿瘤对常规治疗的反应最好。PET的作用将随着使用这些和其他新型示踪剂的进一步临床研究而继续发展。
Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) has been established as a useful tool in the management of patients with non-small cell lung cancer and promises to be as valuable in the clinical management of other cancers. PET imaging with FDG allows the assessment of tumor glucose metabolism in vivo; however, a number of other PET tracers are being used in oncologic research to assess changes in other cellular processes associated with malignant transformation of the cell. [11C]-Labeled methionine and choline are being used to assess changes in cell membrane synthesis; however, small studies have not shown the added information from these tracers to be clinically useful. DNA synthesis can be assessed by measuring the uptake of the thymidine analog 3'-deoxy-3'-[18F]fluorothymidine, which may be more specific for evaluating malignancy without the problem of false-positive results from inflammatory lesions, as seen with FDG. Tumor hypoxia imaging with copper-labeled diacetyl-bis(N(4)-methylthiosemicarbazone) or [18F]fluoromisonidazole may provide a better method of predicting which tumors will respond best to conventional therapy. The role of PET will continue to evolve with further clinical studies using these and other new tracers.